Trastuzumab is the HER2 receptor-specific antibody (Ab), and after binding to the extracellular domain of HER2, with high specificity, it hinders the proliferation of cancer cells that overexpress HER2 [50]. This evidence concerns the gene ERBB2 and cancer.